Abstract
The molecular basis of many leukaemias is now known, allowing precise diagnosis. Treatment of chronic myeloid leukaemia is now possible by targeting of the BCR-ABL tyrosine kinase. The underlying molecular abnormalities in acute leukaemias allow the outlook for individual patients to be assessed at diagnosis and therapy tailored accordingly. Analysis of V(H) genes in B-cell malignant disorders allows these to be placed in the hierarchy of B-cell development and may provide prognostically valuable information.
Original language | English (US) |
---|---|
Pages (from-to) | 1447-1453 |
Number of pages | 7 |
Journal | Lancet |
Volume | 355 |
Issue number | 9213 |
DOIs | |
State | Published - Apr 22 2000 |
ASJC Scopus subject areas
- General Medicine